Goodwin advised Corvidia Therapeutics on the deal Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, closed a $60 million USD Series B funding round. The…
Corvidia Therapeutics’ $60 Million Series B Financing Round
Goodwin advised Corvidia Therapeutics on the deal Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, closed a $60 million USD Series B funding round. The…